> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Allarity’s Stenoparib on FDA Fast Track
- URL: https://www.fdaweb.com/allaritys-stenoparib-on-fda-fast-track/
- Published: 2025-08-26T12:00:00.000Z
- Updated: 2026-09-14T15:20:04.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159759

FDA has granted fast-track designation to Allarity Therapeutics’ stenoparib, an investigational treatment for patients with advanced ovarian cancer. A company [statement](https://allarity.com/press-release/allarity-therapeutics-granted-fda-fast-track-designation-for-stenoparib-for-the-treatment-of-advanced-ovarian-cancer/?ref=fdaweb.com) describes stenoparib as an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2.

The company says it recently began patient enrollment under a new Phase 2 clinical trial protocol evaluating stenoparib in advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. It says the trial is designed to accelerate clinical development of stenoparib and its DRP companion diagnostic and builds on prior encouraging Phase 2 data showing durable clinical benefit, including patients who have been treated for over 22 months.